Chief Executive Officer
|Posted on:||Tuesday, October 16, 2018|
|Organization:||Empire Discovery Institute (EDI)|
The Empire Discovery Institute (EDI) invites applications and nominations for the position of Chief Executive Officer. Announced by Governor Cuomo in May 2018 , EDI represents a $47 million not-for profit drug discovery and development collaborative formed between three premiere Upstate New York academic, research, and clinical institutions—the University of Rochester, the University at Buffalo, and the Roswell Park Comprehensive Cancer Center—to advance drug discovery throughout New York State. EDI will harness New York's wealth of academic capital and provide resources and expertise needed to convert groundbreaking discoveries in the lab into life-changing treatments and medicines.
EDI is seeking a highly enthusiastic, entrepreneurial leader to build a new drug discovery company unrivaled within New York State. This visionary candidate will work with the EDI Board, its partner institutions, NYS health care companies, venture capital firms, NewYorkBIO, MedTech, and the Tri-Institutional Therapeutics Discovery Institution (Tri-TDI) to transform New York State into an unparalleled life science hub. This unified hub will advance life-saving science to patients and serve as a catalyst for new jobs, new companies and new industry-academic drug discovery collaboration opportunities in Upstate New York and throughout the state.
The Empire Discovery Institute (EDI) is a key component of the larger NYS life sciences initiative. In the FY 2018 budget, New York State enacted a $620 million initiative to spur the growth of a world-class life science research cluster in New York, as well as expand the state's ability to commercialize this research and grow the economy.
This multi-faceted initiative includes $100 million to expand the Excelsior Jobs Program Tax Credit to the life sciences industry, $100 million for a life sciences research and development refundable tax credit program, and $320 million in other forms of investment. This includes state capital grants to support the development of wet-lab and innovation space, operating support and investment capital for early stage life science companies that leverages an additional match of at least $100 million from the private sector.
The Life Science sector encompasses the fields of biotechnology, pharmaceuticals, biomedical technologies, life systems technologies, and includes organizations and institutions that devote the majority of their efforts to the various stages of research, development, technology transfer and commercialization. Every day, firms in this sector are developing new medical and pharmaceutical breakthroughs that have the potential to save lives, whether through new therapies or the early detection of diseases like autism and cancer. These firms are also making significant advancements in the realms of agriculture and environmental biotechnologies, helping create a cleaner and more sustainable future.
By strengthening incentives, investing in the facilities, and improving access to talent and expertise, New York will significantly increase its share of industry-funded research and development, support the commercialization of existing academic research, and usher in the next generation of advanced technologies. Beyond the advancements in science, this initiative will position New York as a magnet for emerging manufacturing- based enterprises, bolstering regional economies and creating thousands of jobs.
At the direction of the EDI Board comprised of representatives from the University of Rochester, University at Buffalo, and Roswell Park Comprehensive Cancer Center, the CEO will have primary responsibility for the operating performance of the EDI. The duties and responsibilities include but are not limited to the following:
Preferred Skills & Knowledge
To apply, click the "Apply Now" link below, select "All other openings" and search posting number 211305.